| Dr Susan Diane Weinman, MD | |
|
17 Adelphi Ave, Providence, RI 02906-4119 | |
| (401) 451-0219 | |
| Not Available |
| Full Name | Dr Susan Diane Weinman |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 17 Adelphi Ave, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215969944 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 9911 (Rhode Island) | Primary |
| Entity Name | Brain & Spine Neurosurgical Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558304212 PECOS PAC ID: 9931175841 Enrollment ID: O20040902000500 |
News Archive
Ventas, Inc. announced today that it has priced a public offering of $275 million aggregate principal amount of 3.25% Senior Notes due 2022 at 99.027% of principal amount.
For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.
Researchers at the University of Pennsylvania School of Medicine have recently clarified the role of the Notch protein in T-cell development. T cells are required for many aspects of immunity, including fighting viral infections, providing cancer surveillance, and regulating multiple aspects of the immune response.
Scientists at Stanford University have identified a gene that may play a role in the development of type 1 diabetes, an autoimmune disease in which the immune system attacks the body's insulin-producing cells. Insulin, a hormone produced by cells of the pancreas, helps the body to absorb sugars found in food and to maintain blood sugar at appropriate levels.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 9 days ago
| Entity Name | Medop Behavioral Health Associates Of Rhode Island Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013129220 PECOS PAC ID: 7517068992 Enrollment ID: O20070730000476 |
News Archive
Ventas, Inc. announced today that it has priced a public offering of $275 million aggregate principal amount of 3.25% Senior Notes due 2022 at 99.027% of principal amount.
For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.
Researchers at the University of Pennsylvania School of Medicine have recently clarified the role of the Notch protein in T-cell development. T cells are required for many aspects of immunity, including fighting viral infections, providing cancer surveillance, and regulating multiple aspects of the immune response.
Scientists at Stanford University have identified a gene that may play a role in the development of type 1 diabetes, an autoimmune disease in which the immune system attacks the body's insulin-producing cells. Insulin, a hormone produced by cells of the pancreas, helps the body to absorb sugars found in food and to maintain blood sugar at appropriate levels.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 9 days ago
| Entity Name | Prospect Chartercare Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629493135 PECOS PAC ID: 0840416657 Enrollment ID: O20140730001883 |
News Archive
Ventas, Inc. announced today that it has priced a public offering of $275 million aggregate principal amount of 3.25% Senior Notes due 2022 at 99.027% of principal amount.
For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.
Researchers at the University of Pennsylvania School of Medicine have recently clarified the role of the Notch protein in T-cell development. T cells are required for many aspects of immunity, including fighting viral infections, providing cancer surveillance, and regulating multiple aspects of the immune response.
Scientists at Stanford University have identified a gene that may play a role in the development of type 1 diabetes, an autoimmune disease in which the immune system attacks the body's insulin-producing cells. Insulin, a hormone produced by cells of the pancreas, helps the body to absorb sugars found in food and to maintain blood sugar at appropriate levels.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Susan Diane Weinman, MD 17 Adelphi Ave, Providence, RI 02906-4119 Ph: (401) 331-1946 | Dr Susan Diane Weinman, MD 17 Adelphi Ave, Providence, RI 02906-4119 Ph: (401) 451-0219 |
News Archive
Ventas, Inc. announced today that it has priced a public offering of $275 million aggregate principal amount of 3.25% Senior Notes due 2022 at 99.027% of principal amount.
For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.
Researchers at the University of Pennsylvania School of Medicine have recently clarified the role of the Notch protein in T-cell development. T cells are required for many aspects of immunity, including fighting viral infections, providing cancer surveillance, and regulating multiple aspects of the immune response.
Scientists at Stanford University have identified a gene that may play a role in the development of type 1 diabetes, an autoimmune disease in which the immune system attacks the body's insulin-producing cells. Insulin, a hormone produced by cells of the pancreas, helps the body to absorb sugars found in food and to maintain blood sugar at appropriate levels.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 9 days ago
Dr. Dana Siperstein, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 167 Point St, Providence, RI 02903 Phone: 401-793-8808 Fax: 401-793-8851 | |
Giuseppe Salvatore D'amelio Iv, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 167 Point St, Providence, RI 02903 Phone: 401-793-8808 | |
Eugenie Atallah, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-606-2645 Fax: 401-606-4386 | |
Dr. Luisa Skoble, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5448 Fax: 401-444-6119 | |
Arnaldo A Berges, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Jane Brown 5s, Providence, RI 02903 Phone: 401-444-5448 Fax: 401-444-6119 | |
Sharath Ponnappa Puttichanda, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 345 Blackstone Blvd, Providence, RI 02906 Phone: 401-455-6346 Fax: 401-455-6532 | |
Loreen Phyllis Carol Pirnie, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5448 |